India has potential to increase Covid-19 testing 10-fold: Kiran Mazumdar-Shaw

Bloomberg October 16 | Updated on October 16, 2020 Published on October 16, 2020

Mazumdar-Shaw, who in August was infected with Covid-19 and experienced mild symptoms, advocates early diagnosis to treat the infection

India needs to aggressively ramp up coronavirus testing capacity as it can’t afford another lockdown or a wave of new active cases hitting hospitals, according to the head of one of the country’s largest drug makers.

“While some states are doing better than others, as a whole we are way below the testing levels of other countries,” Kiran Mazumdar-Shaw, the founder and chairman of Biocon Ltd, said at the Bloomberg India Economic Forum on Thursday. “We need to ramp up our testing — the number of active cases are manageable at this point in time, but if the active cases start surging, we simply don’t have the capacity.”

India, which in March imposed the largest nationwide lockdown globally in response to the pandemic, was taken by surprise by the surging number of infections when it started removing the restrictions, Mazumdar-Shaw said. Now more than 70 lakh people in the South Asian nation have been infected with Covid-19, the second-largest outbreak in the world.

Also read: Biocon to roll out phase-4 post-marketing surveillance for Itolizumab to treat Covid-19 patients

With about 830 tests per million, India’s current virus testing rates are among the lowest in the world, according to most recent data from Johns Hopkins University. The steady rise in cases is making it harder for Prime Minister Narendra Modi to revive an economy that shrank 24 per cent in the quarter ended June.

Ad-hoc manner

“We are going about it in an ad-hoc manner, opinions count and science is not being looked at rationally,” said Mazumdar-Shaw, 67, who in August was infected with Covid-19 and experienced mild symptoms. She advocated early diagnosis to treat the infection and recover faster.

Watch: Covid-19: Biocon's Kiran Mazumdar Shaw tests positive

Fortunately, India has a youthful population that has kept fatalities low, she said, along with a large vaccine production capacity with multiple firms currently holding clinical trials. The biggest challenge for the country will be building up cold chain logistics to distribute vaccines across India in a short period of time, Mazumdar-Shaw said.

“I do hope by the end of November that we are able to say we have a plan and digital platforms to help roll out vaccines,” she said.

The race to develop an inoculation against Covid-19, involving developers in more than 30 countries, has fostered cross-border collaboration and high-stakes competition. Modi’s administration had promised an indigenous vaccine as early as mid-August, a claim the government and its apex medical research body has since walked back.

Vaccine nationalism

By year end or January, a few vaccine emergency use authorisations will likely be approved by different regulators, including India’s, Mazumdar-Shaw said. Quantities will be scarce at first, but will ramp up very quickly, she said.

Still, public health specialists have warned that vaccine nationalism could result in the pandemic lasting longer, by preventing the most efficient allocation of shots to prevent Covid-19. Some countries are trying to buy the first place in line for supplies in the event an experimental vaccine proves effective, even though many have signed up to an access collaboration called COVAX.

“Unfortunately, it is likely to play out in an unfair way — countries are becoming very self-centered,” Mazumdar-Shaw said. “It doesn’t protect you from your neighbouring country which isn’t vaccinated — this is a global pandemic, we are all in it together, we need to be a collective force.”

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on October 16, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.